nature portfolio

Corresponding author(s):	Tony Jun Huang
Last updated by author(s):	Aug 30, 2024

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

_				
5	ta:	ŤΙ	ς†	ICS

Fora	all st	atistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Cor	nfirmed
	x	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	x	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	×	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
	x	A description of all covariates tested
×		A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	X	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
x		For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
x		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
×		For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
x		Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated
		Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection

Image J Version 1.54d 30 March 2023 was used to collect the rotation speed of cells and cell fluorescence. Comsol Multiphysics 5.6 (COMSOL AB, Sweden) was utilized to perform the numerical simulation. Matlab R2022a was utilized to extract cell deformation.

Data analysis

Origin 2018 64Bit was used in data analysis

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about <u>availability of data</u>

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The authors declare that all data supporting the findings of this study are available within the article and the supplementary materials. Further information is available from the corresponding author upon reasonable request.

Research involving human participants, their data, or biological material Policy information about studies with human participants or human data. See also policy information about sex, gender (identity/presentation),

and sexual orientation	on and <u>race, et</u>	thnicity and racism.
Reporting on sex and	d gender	N/A
Reporting on race, ethnicity, or other socially relevant groupings		N/A
Population character	ristics	N/A
Recruitment		N/A
Ethics oversight		N/A
Note that full informati	ion on the appro	oval of the study protocol must also be provided in the manuscript.
Field-spe	cific re	porting
Please select the one	e below that is	the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
x Life sciences	Ве	ehavioural & social sciences
For a reference copy of the	e document with a	all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>
Life scien	ces stu	ıdy design
All studies must disc	lose on these p	points even when the disclosure is negative.
Sample size	All samples (cell	s) were counted by assessing cell density under a microscope
Data exclusions	N/A	
Replication	All attempts at r	replication were successful
Randomization	The allocation w	vas random
Blinding	N/A	
We require information	n from authors a	Decific materials, systems and methods about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.
system of method liste	tu is relevant to y	your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.
Materials & exp		·
n/a Involved in the	e study	n/a Involved in the study
		Flow cytometry
Animals and	other organism	S
X Clinical data		
Dual use research of concern		
✗ ☐ Plants		

Eukaryotic cell lines

Policy information about <u>cell lines and Sex and Gender in Research</u>		
Cell line source(s)	Michigan Cancer Foundation-7 (MCF7)	
Authentication	We purchased new cells directly from ATCC	
Mycoplasma contamination	The cell lines were not tested with Mycoplasma contamination	
Commonly misidentified lines (See <u>ICLAC</u> register)	Name any commonly misidentified cell lines used in the study and provide a rationale for their use.	

Plants

Seed stocks	N/A
Novel plant genotypes	N/A
Authentication	N/A